Biomarin Pharmaceutical

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$747,313
$745,740
$708,658
$648,833
Gross Profit
611,174
557,283
563,900
509,355
EBITDA
195,496
156,415
162,173
136,444
EBIT
171,889
137,409
135,710
109,094
Net Income
124,943
106,080
107,174
88,662
Net Change In Cash
747,313
745,740
708,658
648,833
Free Cash Flow
165,328
200,305
96,923
12,867
Cash
942,842
675,448
972,150
746,996
Basic Shares
196,581
197,147
200,505
199,262

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$2,853,915
$2,419,226
$2,096,039
$1,846,275
Gross Profit
2,273,680
1,842,161
1,612,370
1,375,760
EBITDA
650,528
310,284
267,515
48,026
EBIT
554,102
205,898
165,546
-60,013
Net Income
426,859
167,645
141,561
-64,080
Net Change In Cash
2,853,915
2,419,226
2,096,039
1,846,275
Cost of Revenue
-61,882
Free Cash Flow
475,423
51,648
44,362
185,311
Cash
942,842
755,127
724,531
587,276
Basic Shares
196,708
191,595
188,963
182,852

Earnings Calls

Quarter EPS
2024-12-31
$0.92
2024-09-30
$0.55
2024-06-30
$0.56
2024-03-31
$0.46